<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975907</url>
  </required_header>
  <id_info>
    <org_study_id>CT053-MM-01</org_study_id>
    <nct_id>NCT03975907</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate BCMA Car-T (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>An Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T） Infusion in Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carsgen Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carsgen Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm study to evaluate the safety and tolerability of treatment
      with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is composed of two stages, Phase I stage is for dose escalation and recommendation
      of phase 2 dose, and Phase II stage is to Detailed Description: verify the efficacy and
      safety of the dose proposed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase I is an open-label, dose escalation study and 2 cohorts to evaluate the safety and tolerability of treatment with CT053 and to determine maximum tolerable dose (MTD) and the Recommended Phase 2 Dose (RP2D) for CT053.
Phase 2 is a single-arm, open, multi-center study, to evaluate the efficacy and safety of CAR-BCMA T cells (CT053) in subjects with RR/MM.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1, Safety and tolerability: dose limiting toxicity</measure>
    <time_frame>28days post administration of CAR-T-cells</time_frame>
    <description>dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>overall response rate (ORR)=（sCR+CR+VGPR+PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>Minimal residual disease (MRD) negativity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>TTR TIme to Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>Complete Response (CR) /stringent Complete Response (sCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>≥Very Good Partial Response (VGPR), including VGPR, CR, sCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>ORR at Wk12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion</measure>
    <time_frame>3 months post administration of CAR-T-cells</time_frame>
    <description>CBR, clinical benefit rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of CAR-BCMA T cell therapy</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>AE&amp;SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (the cell persistence duration in peripheral blood)</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Copy numbers of CAR-BCMA gene in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (the cell persistence duration in peripheral blood)</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Number of CAR positive cells in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of CAR-BCMA T cell therapy</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>positivity of ADA (Anti-CAR-T antibody)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Overal response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Complete Response (CR) /stringent Complete Response (sCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>≥Very Good Partial Response (VGPR), including VGPR, CR, sCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Duration of Response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Clinical Benefit Rate (CBR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Time to Response (TTR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Minimal residual disease (MRD) negativity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Progression Free Survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint of CAR-BCMA T cells after infusion</measure>
    <time_frame>through 24 months post administration of CAR-T-cells</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CAR-BCMA T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-BCMA T Cells</intervention_name>
    <description>The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.</description>
    <arm_group_label>CAR-BCMA T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients and legally acceptable representative must have voluntarily signed ICF and
             willing to complete the study procedure, after fully understanding of the study.

          2. Age ≥ 18 years and ≤ 75 years, male or female

          3. The patients have received at least 3 prior regimen for MM, (Induction therapy
             followed by autologous transplantation[ASCT] and maintenance therapy represents one
             line of therapy, those who have not been treated with ASCT should have documented
             rationale); For each line of therapy, the patient should have received at least one
             standard treatment cycle (2016 IMWG) unless the best response to the treatment line is
             documented as progressive diseases (PD)

          4. The patients should have received treatment with at least one proteasome inhibitor AND
             one immunomodulatory drug, and have ever been relapsed or deteriorated after treatment
             with at least one regimen consisting of above-mentioned medications (combination or
             single use)；

          5. Patient should be relapsed within 12 months after the last line of therapy, or not
             achieved at least minimal response (MR) or disease progressed within 60 days after
             last line of therapy (IMWG criteria 2016), with documented evidence.

          6. The patients should have measurable disease based on at least one of the following
             parameters：

               -  Serum M-protein ≥ 10 g/L;

               -  Urine M-protein ≥ 200 mg/24 hrs;

               -  For those whose Serum or Urine M- protein dose not meed the measurable criteria
                  but the light chain type, serum free light chain (FLC): involved FLC level ≥ 10
                  mg/dL (100 mg/L) provided serum FLC ratio is abnormal

          7. Estimated life expectancy &gt; 12 weeks

          8. ECOG performance score 0-1；

          9. Sufficient venous access for leukapheresis collection, and no other contraindications
             to leukapheresis

         10. Patients should maintain adequate organ function

         11. Women of childbearing age must undergo a serum pregnancy test with negative results
             before screening and lymphodepletion preconditioning with fludarabine and
             cyclophosphamide, and are willing to use effective and reliable method of
             contraception for at least 1 year after T cell infusion

         12. Men who actively have intercourse with child-bearing potential women must be willing
             to use effective and reliable method of contraception for at least 1 year after T cell
             infusion

        Exclusion Criteria:

          1. Pregnant or lactating women；

          2. P2. Positive for any following tests: human immunodeficiency virus (HIV) antibody,
             Treponema Pallidum antibody, hepatitis C virus (HCV) antibody, hepatitis B virus (HBV)
             surface antigen (HBsAg), HBV e antigen (HBeAg), HBV e antibody, hepatitis B core
             antibody, HBV DNA;

          3. Patients with any uncontrolled active infection including but not limited to active
             tuberculosis.

          4. Patients with AEs from previous treatment that have not recovered to Common
             Terminology Criteria for Adverse Events (CTCAE) ≤ 1, excluding hair loss, neuropathy
             and other events that the treating physician can determine to be tolerable.

          5. Patients who have ever had any CAR T cell therapy；

          6. Patients who have ever had anti-BCMA therapy；

          7. Patients have received allogeneic stem cell transplantation for treating multiple
             myeloma;

          8. Patients have received autologous stem cell transplantation less than 12 weeks before
             leukapheresis；

          9. Patients have received any anti-cancer treatment within 14 days before leukapheresis
             including but not limited to cytotoxic therapy, proteasome inhibitors,
             immunomodulatory agents, targeted therapies, epigenetic therapy or experimental drug
             therapy. If the field of radiation covers ≤ 5% of the bone marrow, the subjects are
             eligible to participate in the study regardless of the radiotherapy end date；

         10. Patients have received ≥ 5 mg prednisone daily or other equivalent dose of steroids
             within 14 days before leukapheresis or lymphodepletion；

         11. Patients have plasma cell leukemia, Waldenström macroglobulinemia, POEMS
             (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin
             changes) syndrome or AL amyloidosis；

         12. Patients have been administered live attenuated vaccine 4 weeks before leukapheresis
             or lymphodepletion

         13. Patients allergic to component of study treatment.

         14. Patients have any of the condition as following within 6 months of ICF sign-off: New
             York Heart Association (NYHA) stage III or IV congestive heart failure, angina
             pectoris, myocardial infarction, coronary artery bypass graft, stroke (excluding
             lacunar stroke), history of clinically significant arrhythmia including but not
             limited to ventricular arrhythmia, significant QT interval prolongation, uncontrolled
             blood pressure as defined as systolic &gt; 160 mmHg, diastolic &gt; 100 mmHg, uncontrolled
             diabetes mellitus, pulmonary thrombolism, other conditions that investigators believe
             that participating in this clinical trial may endanger the health of the patients

         15. Patients are known to have active autoimmune diseases including but not limited to
             psoriasis, rheumatoid arthritis and other needs of long-term immunosuppressive therapy

         16. patients are oxygen dependent as defined by the blood oxygen saturation (finger oxygen
             detection method) can be maintained &gt; 95% only by oxygen inhalation before
             leukapheresis

         17. Patients with second malignancies in addition to MM are not eligible if the second
             malignancy has required treatment within the past 5 years or is not in complete
             remission. There are two exceptions to this criterion: successfully treated cervical
             carcinoma in situ and non-metastatic basal cell skin carcinoma

         18. Patients have central nervous system (CNS) metastases or CNS involvement (including
             cranial neuropathies or mass lesions and leptomeningeal disease). Patients with
             history of spinal cord compression from MM are eligible provided spinal cord
             compression has been treated with surgery or radiation at least 28 days prior to study
             entry

         19. Patients are unable or unwilling to comply with the requirements of clinical trial

         20. Patients have received major surgery 2 weeks prior to leukapheresis or 4 weeks prior
             to lymphodepletion and after the study treatment (excluding cataract and other local
             anesthesia)

         21. Patients are relatives to investigator or his/her staff, or those who may have an
             interest in the investigator and/or his/her staff.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenming CHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhengzheng FU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zonghai LI, MD</last_name>
    <phone>8621-64355922</phone>
    <email>zonghaili@carsgen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaochen DONG</last_name>
    <phone>8621-64355922</phone>
    <email>xiaochendong@carsgen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chaoyang hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenming Chen, MD</last_name>
      <phone>010-85231000</phone>
      <email>13910107759@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengcheng Fu, MD</last_name>
      <phone>0512-65223637</phone>
      <email>fuzhengzheng@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>car-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

